Company: STAA
Filing Date: 2025-08-29
Form Type: PREM14A
Source: 0001193125-25-192889
Chunk: 78

Company: STAAR SURGICAL CO
Filing Date: 2025-08-29
Form: PREM14A
Chunk 78
---
 the terms and subject to the conditions set forth in the Merger Agreement, are advisable, fair to and in the best interests of STAAR and its stockholders, approved, adopted and declared advisable the execution and delivery of, and entry into, the Merger Agreement, and directed that the Merger Agreement be submitted to the STAAR stockholders for adoption at the Special Meeting.

The Board unanimously recommends that you vote: (1) “FOR” the Merger Proposal and (2) “FOR” the Compensation Proposal.

-47-

Reasons for the Merger In evaluating the transactions contemplated by the Merger Agreement, including the Merger, the Board consulted with STAAR management and STAAR’s outside legal and financial advisors and, in reaching its determinations and making its recommendations, the Board considered a number of factors, including the following:

| • |     | Value of Merger Consideration Relative to Value of Standalone Prospects of STAAR. The Board considered the                                                                                                                                         
 opportunities, risks and uncertainties inherent in STAAR’s ability to execute its standalone business plan as an independent public company, and its belief that $28.00 per share in cash represents an attractive and comparatively certain value 
 for STAAR stockholders relative to the risk-adjusted prospects for STAAR on a standalone basis. Specifically, among other things, the Board considered:                                                                                            |

| • |     | the Board’s knowledge of the business, assets, operations, financial condition, earnings and prospects of                     
 STAAR, as well as the Board’s knowledge of the current and prospective environment in which STAAR and its businesses operate; |

| • |     | the fact that the price of STAAR’s common stock has decreased over the last several years, with a                                                                                                                                             
 significant decline in the beginning of 2025, and the risk that the price of STAAR common stock could be negatively impacted if the Company failed to meet investor expectations, including if STAAR failed to meet its or analyst growth and 
 profitability objectives;                                                                                                                                                                                                                     |

| • |     | the risk that STAAR may not be able to achieve projected financial performance, including the performance 
 contemplated by the Projections;                                                                          |

| • |     | risks associated with global macroeconomic conditions, including the potential impact of such conditions on 
 demand for the Company’s cash-pay premium lenses;                                                           |

| • |     | risks associated with the Company’s high concentration of business in China, including the uncertainty                                                                                                                                            
 regarding the timing and durability of a recovery in refractive procedural volumes in China,